WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The protein tyrosine phosphatase SHP2 plays a key role in activating RAS signaling, but its inhibitors are widely resistant in colorectal cancer (CRC). We reveal WWP1-PTEN-AKT signaling pathway is involved in the resistance of SHP2 inhibition. Combined inhibition of WWP1 and SHP2 exerts a synergistic lethal effect in CRC cells. Expression levels of WWP1 and SHP2 contribute to prognostic modeling in CRC patients. These findings may assist in individual clinical decision-making and clinical trial design, especially for patients with KRAS-mutant CRC.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Gastrointestinal Cancer
Life Sciences > Biological Sciences > Cancer Biology > Cancers > Gastrointestinal Cancer
Pharmacy
Life Sciences > Health Sciences > Pharmacy
Molecular Biology
Life Sciences > Biological Sciences > Molecular Biology

Related Collections

With collections, you can get published faster and increase your visibility.

Antibody-drug conjugates for solid tumors

Antibody drug conjugates (ADCs) have revolutionized the field of oncology with more than 100 ADCs in clinical development for different solid tumors. In this series, we will comprehensively review the clinical development of ADCs in different solid tumors, and how ADCs are replacing traditional chemotherapy in oncology.

Publishing Model: Open Access

Deadline: Jul 15, 2025

Applications of Artificial Intelligence in Cancer

In this cross-journal collection between Nature Communications, npj Digital Medicine, npj Precision Oncology, Communications Medicine, Communications Biology, and Scientific Reports, we invite submissions with a focus on artificial intelligence in cancer.

Publishing Model: Open Access

Deadline: Dec 30, 2024